- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04005638
Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia (BIOCAI)
Study Overview
Status
Intervention / Treatment
Detailed Description
Our department follows about 350 patients with immune thrombocytopenia (ITP), 50 with autoimmune hemolytic anemia (AHA), and about thirty patients for autoimmune neutropenia and erythroblastopenia. The number of new patients per year is about 50. The investigators are working since several years on different research topics concerning ITP and AHA.
In the field of ITP, the investigators are working on abnormalities of megakaryopoiesis present in a particular subgroup of patients. The investigators seek to identify the molecular mechanisms underlying this platelet-forming disorder. This research is done within the INSERM U1034 unit of the University of Bordeaux.
In AHA, The investigators are working on the role of regulatory CD8+ T lymphocytes and the interest of low doses of Interleukin-2 in their treatment. This part is carried out within the CNRS unit UMR 5164 ImmunoConcept. The biological collection the investigators wish to create will be available for basic research projects and may be available to the pharmaceutical industry as part of the development of new molecules.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Isabelle RAYMOND, Pharm
- Email: isabelle.raymond@chu-bordeaux.fr
Study Contact Backup
- Name: Jean-François VIALLARD, Prof
- Phone Number: +33 05.57.65.64.83
- Email: jean-françois.viallard@chu-bordeaux.fr
Study Locations
-
-
-
Pessac, France
- Recruiting
- CHU de Bordeaux - service de médecine interne
-
Contact:
- Isabelle RAYMOND, Pharm
- Email: isabelle.raymond@chu-bordeaux.fr
-
Sub-Investigator:
- Estibaliz LAZARO, Prof
-
Contact:
- Jean-François VIALLARD, Prof
- Phone Number: +33 05.57.65.64.83
- Email: jean-françois.viallard@chu-bordeaux.fr
-
Principal Investigator:
- Jean-François VIALLARD, Prof
-
Sub-Investigator:
- Jean-Luc PELLEGRIN, Prof
-
Sub-Investigator:
- Carine GREIB, MD
-
Sub-Investigator:
- Irene MACHELARD, MD
-
Sub-Investigator:
- Etienne RIVIERE, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients over 16 years old.
- Patients with autoimmune cytopenia according to the definitions reported in the latest update of the French National Care Protocol (PNDS 2017).
- Affiliated person or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
Exclusion Criteria:
- Positivity for HIV, Hepatitis C or B virus.
- Pregnant or lactating woman.
- Patient undergoing treatment for autoimmune cytopenia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Autoimmune Cytopenia
|
45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
12 ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with autoimmune cytopenia at diagnosis, or followed but not treated with a biological library (serum, plasma, DNA)
Time Frame: At baseline (Day 0)
|
At baseline (Day 0)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jean-François VIALLARD, Prof, CHU Bordeaux
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Anemia
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Agranulocytosis
- Leukopenia
- Leukocyte Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Neutropenia
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
- Anemia, Hemolytic
- Anemia, Hemolytic, Autoimmune
Other Study ID Numbers
- CHUBX 2018/13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Thrombocytopenia
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaboratorsRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
argenxWithdrawnPrimary Immune Thrombocytopenia (ITP)
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedAdult Patients | Immune Primary Thrombocytopenia | Splenectomy | TPO-mimeticsItaly
-
Novartis PharmaceuticalsRecruitingPrimary Immune Thrombocytopenia (ITP)China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
-
University Children's Hospital BaselNovartis Pharmaceuticals; Stiftung zur Förderung medizinischer und biologischer... and other collaboratorsActive, not recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
Changzhou No.2 People's HospitalRui Therapeutics Co., LtdNot yet recruitingThrombocytopenia Alloimmune
-
Nahda UniversityRecruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
Clinical Trials on blood sample
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
Centre Hospitalier Universitaire de NīmesNot yet recruitingNarcolepsy Type 1 | Bacterial TranslocationFrance
-
The First Affiliated Hospital of Soochow UniversityRecruitingGraft Vs Host DiseaseChina
-
Meir Medical CenterCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingClassification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) (CILLICORIRCM)Ciliopathies | Bardet-Biedl Syndrome | Nephronophthisis | Senior-Loken Syndrome | Joubert Syndrome | Jeune SyndromeFrance